Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Neovasc Inc. (T:NVCN)

Business Focus: Advanced Medical Equipment & Technology (NEC)

Jan 17, 2023 08:27 am ET
Shockwave Medical to Acquire Neovasc
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the Company (the "Transaction").
Jan 17, 2023 08:00 am ET
Shockwave Medical Announces Agreement to Acquire Neovasc
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc....
Jan 17, 2023 08:00 am ET
Shockwave Medical to Acquire Neovasc
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding...
Jan 17, 2023 07:15 am ET
IIROC Trade Resumption - NVCN
TORONTO, Jan. 17, 2023 /CNW/ - Trading resumes in:
Jan 17, 2023 07:09 am ET
IIROC Trading Halt - NVCN
TORONTO, Jan. 17, 2023 /CNW/ - The following issues have been halted by IIROC:
Nov 28, 2022 05:00 pm ET
Neovasc Announces Progress on COSIRA-II Clinical Trial
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COSIRA-II Clinical Trial ("Trial") status. COSIRA-II is the U.S. Investigational Device Exemption ("IDE") pivotal clinical trial the Company is executing for the Neovasc Reducer™ ("Reducer") towards an approval decision for the device in the United States. The Trial will randomize approximately 380 patients at up to 50 sites in North America. To date, 55 patients have been enrolled at 17 active sites. The Company has undertaken several initiatives to further accelerate enrollment in the Trial, including machine learning technology, expanding the field clinical team, and initiating enrollments in Canada. Neovasc aims to complete randomization in the first half of 2024.
Nov 28, 2022 04:45 pm ET
Neovasc Announces Progress on COSIRA-II Clinical Trial
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal clinical trial the...
Nov 18, 2022 09:05 am ET
Neovasc Comments on European Heart Journal Publication
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal - Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory Angina due to...
Nov 18, 2022 09:05 am ET
Neovasc Comments on European Heart Journal Publication
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that European Heart Journal - Case Reports has published an article titled, "Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy - a Case Report." The article is authored by Dr. Kevin Cheng, et al, at the National Heart and Lung Institute Imperial College London, Royal Brompton Hospital, London.
Nov 10, 2022 04:05 pm ET
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a...
Nov 10, 2022 04:05 pm ET
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 10, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2022.
Nov 08, 2022 09:05 am ET
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new outpatient...
Nov 08, 2022 09:05 am ET
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Centers for Medicare and Medicaid Services ("CMS") has assigned the Neovasc Reducer™ ("Reducer") implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.
Oct 27, 2022 09:00 am ET
Neovasc to Report Third Quarter Financial Results on November 10, 2022
via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief...
Oct 27, 2022 09:00 am ET
Neovasc to Report Third Quarter Financial Results on November 10, 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022.
Sep 20, 2022 09:05 am ET
Neovasc Provides Corporate Update Following Clinical Data Release
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston. Prof. Shmuel Banai, MD, Neovasc...
Sep 20, 2022 09:05 am ET
Neovasc Provides Corporate Update Following Clinical Data Release
New Data Presented on the Neovasc Reducer(TM) in Patients With Microvascular Disease
Sep 16, 2022 09:00 am ET
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24,...
Sep 16, 2022 09:00 am ET
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.
Sep 15, 2022 09:05 am ET
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid Services (“CMS”) development of new codes for the diagnosis and tracking of refractory angina. The new codes...
Sep 15, 2022 09:05 am ET
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 15, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") development of new codes for the diagnosis and tracking of refractory angina. The new codes will be utilized in the current, 10th revision of the International Statistical Classification of Diseases and Related Health Problems Clinical Modification ("ICD-10-CM"). The latest update was published in the ICD-10-CM Tabular List of Diseases and Injuries 2023 Addenda and will be effective October 1, 2022.
Sep 08, 2022 09:05 am ET
Neovasc Announces Key Events at TCT 2022
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference (“TCT”), hosted by the Cardiovascular Research...
Sep 08, 2022 09:05 am ET
Neovasc Announces Key Events at TCT 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference ("TCT"), hosted by the Cardiovascular Research Foundation ("CRF"), taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022. Members of the Neovasc team will be available at booth 647 in the exhibit hall.
Aug 30, 2022 09:05 am ET
Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
via NewMediaWire – Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New...
Aug 30, 2022 09:05 am ET
Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2022) - Neovasc, Inc. (Neovasc or the Company) (NASDAQ: NVCN) (TSX: NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New York City. Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 1:30 pm ET on Tuesday, September 13, 2022.
Aug 11, 2022 04:05 pm ET
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Generated revenues of $818,000, a quarterly record and a...
Aug 11, 2022 04:05 pm ET
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2022.
Jul 28, 2022 09:00 am ET
Neovasc to Report Second Quarter Financial Results on August 11, 2022
via NewMediaWire – Neovasc Inc. (NASDAQ ,  TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial...
Jul 28, 2022 09:00 am ET
Neovasc to Report Second Quarter Financial Results on August 11, 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on August 11, 2022.
Jul 26, 2022 09:05 am ET
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”)...
Jul 26, 2022 09:05 am ET
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 26, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the United States Food and Drug Administration ("FDA") has approved a protocol supplement to the COSIRA-II Investigational Device Exemption ("IDE") Trial. The approval expands the number of patients eligible for treatment in the trial and adds two previously planned imaging sub-studies designed to provide insights into the safety and mechanism of action of the Neovasc Reducer™ ("Reducer"). The timing of the approval is ahead of the Company's internal target and will allow for additional patients to be treated.
Jul 05, 2022 09:05 am ET
Neovasc Announces Direct Sales Operations in United Kingdom
via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the company has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022. The company has hired its...
Jul 05, 2022 09:05 am ET
Neovasc Announces Direct Sales Operations in United Kingdom
Expansion Driven by NICE Guidelines and Enhanced Reimbursement for the Neovasc Reducer(TM)
Jun 08, 2022 09:05 am ET
Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022....
Jun 08, 2022 09:05 am ET
Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022. Neovasc's Chief Operating Officer, Bill Little, will be presenting at 1:45 pm ET on Wednesday, June 15.
May 23, 2022 04:05 pm ET
Neovasc to Participate in H.C. Wainwright Global Investment Conference
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc’s...
May 23, 2022 04:05 pm ET
Neovasc to Participate in H.C. Wainwright Global Investment Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 23, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc's President and Chief Executive Officer, will be presenting at 11:00 am ET on Wednesday, May 25.
May 16, 2022 09:05 am ET
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (the “Nasdaq”) informing the Company that it has regained compliance with...
May 16, 2022 09:05 am ET
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 16, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification from the Nasdaq Stock Market LLC (the "Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.
May 12, 2022 04:05 pm ET
Neovasc Announces First Quarter Financial Results and Provides Corporate Update
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the quarter ended March 31, 2022. Recent Highlights ·       Achieved Q1 revenue of approximately $611,000, an increase of 35%...
May 12, 2022 04:05 pm ET
Neovasc Announces First Quarter Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 12, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the quarter ended March 31, 2022.
Apr 29, 2022 09:05 am ET
Neovasc to Report First Quarter Financial Results on May 12, 2022
via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial...
Apr 29, 2022 09:05 am ET
Neovasc to Report First Quarter Financial Results on May 12, 2022
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 29, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on May 12, 2022.
Apr 28, 2022 09:05 am ET
Neovasc Comments on European Heart Journal Publication
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the European Heart Journal has published an article entitled, “Impact of the Coronary Sinus Reducer on Absolute Blood Flow and Microvascular...
Apr 28, 2022 09:05 am ET
Neovasc Comments on European Heart Journal Publication
Report demonstrates objective improvements in patients suffering from microvascular dysfunction
Apr 27, 2022 04:05 pm ET
Neovasc Announces Effective Date of Share Consolidation
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter...
Apr 27, 2022 04:05 pm ET
Neovasc Announces Effective Date of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation (reverse stock split) (the "Consolidation") of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every twenty-five (25) pre-Consolidation Common Shares. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 68,228,061 Common Shares to approximately 2,729,107 Common Shares. The Common Shares are expected to commence trading on the Toronto Stock Exchange (the "TSX") and on the Nasdaq Capital Market (the "Nasdaq") on a post-Consolidation basis on or about the opening of trading on April 29, 2022.
Apr 20, 2022 09:05 am ET
Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen,...
Apr 20, 2022 09:05 am ET
Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX : NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen, Neovasc's Chief Executive Officer, will be presenting at 4:00 pm ET on Monday, May 2.
Apr 13, 2022 08:05 am ET
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver,...
Apr 13, 2022 08:05 am ET
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
New York, New York--(Newsfile Corp. - April 13, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) "Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver, B.C. (the "Meeting").
Mar 24, 2022 09:05 am ET
Neovasc Announces Consolidation and Extension of Convertible Debt
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter...
Mar 24, 2022 09:05 am ET
Neovasc Announces Consolidation and Extension of Convertible Debt
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that, pursuant to a Restated Securities Purchase Agreement with Strul Medical Group LLC ("SMG"), on a private placement basis (the "Private Placement"), it has issued an amended and restated convertible note (the "2022 Restated Note").
Mar 10, 2022 04:05 pm ET
Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021. Highlights Achieved record revenue in Q4 of $759,000, an increase of 48%...
Mar 10, 2022 04:05 pm ET
Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 10, 2022) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021.
Feb 24, 2022 09:00 am ET
Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief...
Feb 24, 2022 09:00 am ET
Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on March 10, 2022.
Feb 08, 2022 09:05 am ET
Neovasc Announces German Reimbursement Renewal and Commercial Progress
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the...
Feb 08, 2022 09:05 am ET
Neovasc Announces German Reimbursement Renewal and Commercial Progress
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022. Additionally, the Company announced the 500th patient has been treated in Germany.
Feb 04, 2022 09:05 am ET
Independent Publication Reports Neovasc Reducer(TM) Demonstrates Cost Savings
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 4, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc ReducerTM ("Reducer").
Feb 04, 2022 09:05 am ET
Independent Publication Reports Neovasc Reducer™ Demonstrates Cost Savings
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc  Reducer™ (“Reducer”). The two analyses, authored by Americo...
Feb 02, 2022 09:05 am ET
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation,...
Feb 02, 2022 09:05 am ET
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 2, 2022) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the Southern District of New York. The consolidated amended complaint was dismissed in its entirety with prejudice and without leave to amend.
Jan 20, 2022 09:05 am ET
Neovasc Announces Publication Supporting the Neovasc Reducer(TM) Device
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of an article entitled, "The Effectiveness of CS Reducer for the Treatment of Refractory Angina - a Meta-Analysis" in the Canadian Journal of Cardiology.
Jan 20, 2022 09:05 am ET
Neovasc Announces Publication Supporting the Neovasc Reducer™ Device
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “The Effectiveness of CS Reducer for the Treatment of Refractory Angina – a Meta-Analysis” in the Canadian...
Jan 18, 2022 09:05 am ET
Neovasc Announces Case Series of First U.S. Reducer Implants Published In Peer-Reviewed Journal
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™...
Jan 18, 2022 09:05 am ET
Neovasc Announces Case Series of First U.S. Reducer Implants Published in Peer-Reviewed Journal
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™ ("Reducer") under a compassionate use protocol in the United States. The patients were treated under the care of Ryan Gindi, M.D., and the procedures were performed by Gerald Koenig, M.D., Ph.D, both from the Division of Cardiology, Henry Ford Hospital, Detroit. Following the commencement of the COSIRA-II Trial in the United States, qualifying patients are now eligible to be treated in a clinical trial for the device.
Jan 06, 2022 09:05 am ET
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022.  A recorded...
Jan 06, 2022 09:05 am ET
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 6, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022. A recorded presentation by Fred Colen, Neovasc's Chief Executive Officer, will be available on the conference website starting at 7:00 am EST on Monday, January 10. The recording will be archived for 90 days.
Jan 05, 2022 09:05 am ET
Neovasc Announces First Patient Enrollment in COSIRA-II Trial
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced enrollment of the first patient in the COSIRA-II clinical trial. COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a...
Jan 05, 2022 09:05 am ET
Neovasc Announces First Patient Enrollment in COSIRA-II Trial
COSIRA-II Trial Designed to Study the Neovasc Reducer(TM) for Patients with Refractory Angina
Dec 01, 2021 09:05 am ET
Neovasc to Participate in Sidoti December Virtual Microcap Conference
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that its management team will be participating in the Sidoti December Virtual Microcap Conference to be held December 8-9, 2021.  Fred Colen,...
Dec 01, 2021 09:05 am ET
Neovasc to Participate in Sidoti December Virtual Microcap Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the Sidoti December Virtual Microcap Conference to be held December 8-9, 2021. Fred Colen, President and Chief Executive Officer, will give a presentation on Wednesday, December 8 at 3:15 pm EST. A link to the live webcast of the presentation will be available in the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.
Nov 30, 2021 09:51 am ET
Neovasc Reducer(TM) System Receives National Reimbursement in France
First therapy to receive newly established French reimbursement designation
Nov 30, 2021 09:40 am ET
Neovasc Reducer™ System Receives National Reimbursement in France
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer™ (“Reducer”) system has been granted Prise en Charge Transitoire (“PECT”) reimbursement in France by the national health...
Nov 24, 2021 01:24 pm ET
Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule...
Nov 24, 2021 01:24 pm ET
Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has granted an additional 180 calendar day period within which to evidence compliance with the $1.00 bid price requirement following the expiration of the current compliance period on November 22, 2021.
Nov 24, 2021 09:34 am ET
The National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Reducer System
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the United Kingdom’s Interventional Procedures Programme at the National Institute for Health and Care Excellence (“NICE”) has issued guidance...
Nov 24, 2021 09:29 am ET
The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the United Kingdom's Interventional Procedures Programme at the National Institute for Health and Care Excellence ("NICE") has issued guidance supporting the implantation of the Neovasc Reducer™ ("Reducer") in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest pain when other treatment options have failed or are not possible.
Nov 09, 2021 04:21 pm ET
Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update
via NewMediaWire --Neovasc, Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2021.  Third Quarter Highlights Strong progress against all three...
Nov 09, 2021 04:05 pm ET
Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 9, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2021.
Nov 01, 2021 09:05 am ET
Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial...
Nov 01, 2021 09:05 am ET
Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on November 9, 2021.
Oct 21, 2021 09:05 am ET
Neovasc Reducer(TM) Featured in Polish Heart Journal
Publication Highlights Device Success in Chronic Total Occlusions of the Right Coronary Artery
Oct 21, 2021 09:05 am ET
Neovasc Reducer™ Featured in Polish Heart Journal
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer™ (“Reducer”) is featured in an article published in the latest issue of the Polish Heart Journal. Entitled “Efficacy of...
Sep 28, 2021 09:05 am ET
Neovasc REDUCER-I Study Published in EuroIntervention Journal
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label...
Sep 28, 2021 09:05 am ET
Neovasc REDUCER-I Study Published in EuroIntervention Journal
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 28, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)" in the September 2021 issue of the journal EuroIntervention.
Sep 23, 2021 09:05 am ET
Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021.  Bill Little,...
Sep 23, 2021 09:05 am ET
Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 23, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021. Bill Little, Neovasc's Chief Operating Officer, will give a presentation on Wednesday, September 29 at 4:00 pm EDT. A link to the live webcast of the presentation will be available in the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.
Sep 16, 2021 09:05 am ET
Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial.  Following multiple...
Sep 16, 2021 09:05 am ET
Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
Company on Schedule to Commence Trial Late This Year
Aug 30, 2021 04:05 pm ET
Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
via NewMediaWire – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021. A...
Aug 30, 2021 04:05 pm ET
Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021. A pre-recorded company presentation will be available beginning at 7:00 am EDT on September 13 through the conference website and the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.
Aug 17, 2021 09:05 am ET
Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA)....
Aug 17, 2021 09:05 am ET
Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 17, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA). Following multiple productive discussions with FDA over the past several months, the protocol for the previously approved COSIRA-II study has been supplemented in consideration of additional experience and key questions arising from the October 2020 Circulatory Systems Devices Panel Meeting regarding the Neovasc Reducer™ ("Reducer").
Aug 10, 2021 04:05 pm ET
Neovasc Announces Second Quarter 2021 Financial Results
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the second quarter ended June 30, 2021. Second Quarter Highlights Generated...
Aug 10, 2021 04:05 pm ET
Neovasc Announces Second Quarter 2021 Financial Results
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 10, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2021.
Jul 27, 2021 09:05 am ET
Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021
via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021.  Neovasc’s President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief...
Jul 27, 2021 09:05 am ET
Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc's President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 pm EDT.
Jul 13, 2021 09:05 am ET
Neovasc Announces New Appointments in Regulatory and Clinical Leadership
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has appointed Lisa Becker as Vice President, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as Vice President, Clinical...
Jul 13, 2021 09:05 am ET
Neovasc Announces New Appointments in Regulatory and Clinical Leadership
Neovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical Affairs
Jun 18, 2021 09:05 am ET
Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 18, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study" in the International Journal of Cardiology.
Jun 18, 2021 09:05 am ET
Largest Real-World Registry Supporting Neovasc Reducer™ Safety and Efficacy Outcomes Published in International Journal of Cardiology
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE...
Jun 18, 2021 09:05 am ET
Largest Real-World Registry Supporting Neovasc Reducer™ Safety and Efficacy Outcomes Published in International Journal of Cardiology
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE...
Jun 10, 2021 03:29 pm ET
Neovasc Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runway well into 2024, focusing investments on near term value drivers, and more deeply reviewing the Company's core business activities.
Jun 10, 2021 03:22 pm ET
IIROC Trade Resumption - NVCN
TORONTO, June 10, 2021 /CNW/ - Trading resumes in:
Jun 10, 2021 03:06 pm ET
Neovasc Provides Corporate Update
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its...
Jun 10, 2021 03:01 pm ET
IIROC Trading Halt - NVCN
TORONTO, June 10, 2021 /CNW/ - The following issues have been halted by IIROC:
Jun 07, 2021 09:05 am ET
Neovasc Reducer System Receives First National Reimbursement in Europe
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer® (“Reducer”) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff...
Jun 07, 2021 09:05 am ET
Jun 03, 2021 04:52 pm ET
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C. (the "Meeting").
Jun 03, 2021 04:45 pm ET
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C. (the...
May 25, 2021 04:05 pm ET
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency 
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not...
May 25, 2021 04:05 pm ET
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 25, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from April 12, 2021 to May 21, 2021, the Company no longer meets the minimum bid price requirement.
May 20, 2021 04:05 pm ET
Neovasc Provides Update on German Litigation
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which the...
May 20, 2021 04:05 pm ET
Neovasc Provides Update on German Litigation
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 20, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which the court had found that Edwards Lifesciences LLC ("Edwards") had contributed in part to the invention of the Tiara™ and awarded to Edwards co-entitlement rights to the disputed Tiara™ European patent application. There are no monetary awards associated with these matters and no damages award was recognized.
May 13, 2021 09:35 am ET
Neovasc to Sponsor Symposium on Reducer at EuroPCR
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 13, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ ("Reducer"), highlighting its easy integration into current cardiovascular and microvascular disease treatments. The symposium titled, "Latest clinical evidence and practical aspects to start Reducer therapy in your center," will be presented at the 2021 EuroPCR, taking place digitally from May 18-20, 2021. EuroPCR is a leading opportunity for cardiologists to exchange ideas and latest best practices.
May 13, 2021 09:11 am ET
Neovasc to Sponsor Symposium on Reducer at EuroPCR
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ (“Reducer”), highlighting its easy integration into...
May 10, 2021 09:05 am ET
Neovasc Announces First Patient Enrollment in COSIMA Trial
via NewMediaWire ‒ Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina (“COSIMA”) trial. The...
May 10, 2021 09:05 am ET
Neovasc Announces First Patient Enrollment in COSIMA Trial
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina ("COSIMA") trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who suffers from severe Canadian Cardiovascular Society ("CCS") Class IV angina on a daily basis despite optimal medical treatment. The study is being led by Prof. Tommaso Gori, M.D., Ph.D., University Medical Center, Mainz, Germany.
May 06, 2021 04:05 pm ET
Neovasc Announces First Quarter 2021 Financial Results
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Generated revenue of $451,794 in the quarter as Neovasc...
May 06, 2021 04:05 pm ET
Neovasc Announces First Quarter 2021 Financial Results
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 6, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today reported financial results for the first quarter ended March 31, 2021.
Apr 28, 2021 09:05 am ET
Neovasc Provides Reducer Reimbursement Progress Update
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ (“Reducer”). Expanding reimbursement for the...
Apr 28, 2021 09:05 am ET
Neovasc Provides Reducer Reimbursement Progress Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 28, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ ("Reducer").
Apr 27, 2021 09:05 am ET
Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021
via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN) will report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021.  Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris...
Apr 27, 2021 09:05 am ET
Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 27, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.
Apr 19, 2021 09:05 am ET
Neovasc Comments on EuroIntervention Article
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at...
Apr 19, 2021 09:05 am ET
Neovasc Comments on EuroIntervention Article
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 19, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal EuroIntervention has published an article entitled, "Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina."
Apr 16, 2021 09:27 am ET
Neovasc Provides Tiara TA Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 16, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today announced that the Tiara Transapical system ("Tiara TA") will be unable to receive a European CE mark under the current Medical Device Directive regulations ("MDD") ending on May 26, 2021. The Company is collaborating with its European Notified Body (the "Notified Body") on potential next steps.
Apr 16, 2021 09:05 am ET
Neovasc Provides Tiara TA Update
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations...
Mar 11, 2021 04:05 pm ET
Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter Highlights...
Mar 11, 2021 04:05 pm ET
Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 11, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020.
Mar 04, 2021 09:00 am ET
Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021.  Neovasc President and Chief Executive Officer Fred Colen...
Mar 04, 2021 09:00 am ET
Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 4, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.
Mar 03, 2021 04:30 pm ET
Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference
via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021.  A recorded...
Mar 03, 2021 04:30 pm ET
Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 3, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021. A recorded presentation by Bill Little, Neovasc's Chief Operating Officer, will be available on the Conference website starting at 7:00 am EST on March 9. Company management will also be scheduling one-on-one meetings with investors; meetings may be requested through H.C. Wainwright.
Mar 02, 2021 09:00 am ET
Neovasc Comments on Clinical Cardiology Journal Publication
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer...
Mar 02, 2021 09:00 am ET
Neovasc Comments on Clinical Cardiology Journal Publication
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 2, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal Clinical Cardiology has published an article entitled, "Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study."
Feb 24, 2021 04:05 pm ET
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the...
Feb 24, 2021 04:05 pm ET
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 24, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules").
Feb 17, 2021 09:00 am ET
Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference
via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference that is scheduled to take place from February 24 to 26, 2021. Fred...
Feb 17, 2021 09:00 am ET
Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference
Vancouver, British Columbia--(Newsfile Corp. - February 17, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference that is scheduled to take place from February 24 to 26, 2021. Fred Colen, Neovasc's President and Chief Executive Officer, will present on Friday, February 26, 2021 at 1:00 pm EST.
Feb 12, 2021 03:53 pm ET
Neovasc Announces Closing of US$72 Million Registered Direct Offering of Common Shares Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - February 12, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) announced today that it has closed its previously announced sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for aggregate gross proceeds to the Company of approximately US$72 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company.
Feb 12, 2021 03:34 pm ET
Neovasc Announces Closing of US$72 Million Registered Direct Offering of Common Shares Priced At-The-Market
via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq: NVCN / TSX: NVCN) announced today that it has closed its previously announced sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in...
Feb 10, 2021 07:38 am ET
Neovasc Announces US$72 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for aggregate gross proceeds to the Company of approximately US$72 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company. The Offering is expected to close on or about February 12, 2021, subject to customary closing conditions.
Feb 10, 2021 07:31 am ET
Neovasc Announces US$72 Million Registered Direct Offering Priced At-The-Market
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of...
Feb 09, 2021 09:00 am ET
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the...
Feb 09, 2021 09:00 am ET
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 9, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.
Feb 05, 2021 09:00 am ET
Neovasc Comments on Journal of the American Heart Association Publication
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the Journal of the American Heart Association has published an article entitled, “Angina Severity, Mortality, and Healthcare Utilization Among...
Feb 05, 2021 09:00 am ET
Neovasc Comments on Journal of the American Heart Association Publication
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 5, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Journal of the American Heart Association has published an article entitled, "Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina". The prestigious journal is the official publication of the American Heart Association, and the article offers important insights into the burden of angina on both patients and healthcare systems.
Feb 02, 2021 09:32 am ET
Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 2, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the German Institute for the Hospital Remuneration System("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once again for 2021.
Feb 02, 2021 09:30 am ET
Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina
via NewMediaWire -- Neovasc,  Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the German Institute for the Hospital Remuneration System("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for...
Jan 29, 2021 08:00 am ET
American Medical Association Issues New CPT Code for Neovasc Reducer Procedure
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Category III Code for transcatheter implantation...
Jan 29, 2021 08:00 am ET
American Medical Association Issues New CPT Code for Neovasc Reducer Procedure
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 29, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Category III Code for transcatheter implantation of a coronary sinus reduction device. The code is effective July 1, 2021.
Jan 19, 2021 08:33 am ET
Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy
Vancouver, Bristish Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 19, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that the Neovasc Reducer™ ("Reducer") was prominently featured in three peer reviewed European Journals.
Jan 19, 2021 08:30 am ET
Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today the Neovasc Reducer™ (“Reducer”) was prominently featured in three peer reviewed European Journals.   “Management of refractory angina: an...
Jan 15, 2021 05:14 pm ET
Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received a "not-approvable" letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer™ (Reducer).
Jan 15, 2021 04:58 pm ET
Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer™
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received a “not-approvable” letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer™...
Jan 04, 2021 04:05 pm ET
Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
via NewMediaWire -- Neovasc Inc. (Nasdaq, TSX: NVCN), today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021.  Neovasc President and Chief Executive Officer Fred Colen,...
Jan 04, 2021 04:05 pm ET
Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 4, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021. Neovasc President and Chief Executive Officer Fred Colen, Chief Operating Officer Bill Little, and Chief Financial Officer Chris Clark will be available for one-on-one investor meetings during the event; meetings may be requested through H.C. Wainwright. Additionally, a webcast of Neovasc's recorded company presentation will be available on demand via the H.C. Wainwright conference site beginning at 6:00 am ET on January 11, and on the Neovasc website at https://www.neovasc.com/presos/.
Dec 17, 2020 07:00 am ET
Neovasc Announces Publication of Peer-Reviewed Article in EuroIntervention
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that EuroIntervention, the official journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI), has published...
Dec 17, 2020 07:00 am ET
Neovasc Announces Publication of Peer-Reviewed Article in EuroIntervention
REDUCER I Study Shows Improvement in Chest Pain Symptoms
Dec 15, 2020 07:00 am ET
Neovasc Announces First Neovasc Reducer(TM) Implants in France
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 15, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has completed the first three Neovasc Reducer™ ("Reducer") implants in France. The implants are an important step for Neovasc as the Company continues to expand access for Reducer therapy to patients suffering from refractory angina.
Dec 15, 2020 07:00 am ET
Neovasc Announces First Neovasc Reducer™ Implants in France
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has completed the first three Neovasc Reducer™ (“Reducer”) implants in France. The implants are an important step for Neovasc as the Company...
Dec 14, 2020 06:40 pm ET
Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 14, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from October 30, 2020 to December 11, 2020, the Company no longer meets the minimum bid price requirement.
Dec 14, 2020 06:27 pm ET
Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not...
Dec 10, 2020 05:56 pm ET
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 10, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") , announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US$35 million and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company for the 30 consecutive business days from October 28, 2020 to December 9, 2020, the Company no longer meets the minimum market value requirement.
Dec 10, 2020 05:39 pm ET
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX:NVCN), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is...
Dec 10, 2020 04:40 pm ET
Neovasc Announces Closing of US$6.1 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 10, 2020) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules of an aggregate of 6,230,803 common shares at a price of US$0.9801 per common share. Aggregate gross proceeds to the Company were approximately US$6.1 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company.
Dec 10, 2020 04:30 pm ET
Neovasc Announces Closing of US$6.1 Million Registered Direct Offering Priced At-the-Market
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the...
Dec 08, 2020 09:00 am ET
Neovasc Announces US$6.1 Million Registered Direct Offering Priced At-the-Market
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 8, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 6,230,803 common shares at a purchase price of US$0.9801 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules. Aggregate gross proceeds to the Company are approximately US$6.1 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company. The Offering is expected to close on or about December 10, 2020, subject to satisfaction of customary closing conditions.
Dec 08, 2020 09:00 am ET
Neovasc Announces US$6.1 Million Registered Direct Offering Priced At-the-Market
via NewMediaWire -- Neovasc, Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 6,230,803...
Dec 01, 2020 04:30 pm ET
Neovasc Announces Participation in Noble Capital Markets Virtual Road Show Series
via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for December 8, 2020. The virtual...
Dec 01, 2020 04:30 pm ET
Neovasc Announces Participation in Noble Capital Markets Virtual Road Show Series
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 1, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today announced their participation in Noble Capital Markets' Virtual Road Show Series, presented by Channelchek, scheduled for December 8, 2020.
Nov 16, 2020 04:46 pm ET
Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020. Fred Colen, Neovasc's President and Chief Executive Officer, will deliver a presentation at 11:00 am EST. Mr. Colen will also be joined by Chief Financial Officer Chris Clark, and Chief Operating Officer Bill Little, for investor meetings throughout the day.
Nov 16, 2020 04:33 pm ET
Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum
via NewMediaWire – Neovasc, Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.  Fred Colen, Neovasc’s President...
Nov 05, 2020 04:05 pm ET
Neovasc Announces Third Quarter Financial Results
via NewMediaWire -- Neovasc, Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory...
Nov 05, 2020 04:05 pm ET
Neovasc Announces Third Quarter Financial Results
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 5, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2020.
Oct 28, 2020 07:00 am ET
Neovasc Announces FDA Advisory Panel Result on Neovasc Reducer™ Medical Device for the Treatment of Refractory Angina
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the United States Food and Drug Administration’s (FDA’s) Circulatory System Devices Advisory Panel voted 14 to 4 “in favor” that the Neovasc...
Oct 28, 2020 07:00 am ET
Neovasc Announces FDA Advisory Panel Result on Neovasc Reducer(TM) Medical Device for the Treatment of Refractory Angina
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 28, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the United States Food and Drug Administration's (FDA's) Circulatory System Devices Advisory Panel voted 14 to 4 "in favor" that the Neovasc Reducer™ is safe when used as intended, and voted 1 to 17 "against" on the issue of a reasonable assurance of effectiveness. The third vote was 13 to 3 "against" (2 abstained) on whether the relative benefits outweighed the relative risks.
Oct 22, 2020 09:00 am ET
Neovasc to Report Third Quarter Financial Results on November 5, 2020
via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) today announced that it will report financial results for the quarter ended September 30, 2020 after the market close on November 5, 2020.  Neovasc President and Chief Executive Officer Fred...
Oct 22, 2020 09:00 am ET
Neovasc to Report Third Quarter Financial Results on November 5, 2020
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 22, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced that it will report financial results for the quarter ended September 30, 2020 after the market close on November 5, 2020. Neovasc President and Chief Executive Officer Fred Colen, and Chief Financial Officer Chris Clark will host a conference call to review the company's results at 4:30 PM Eastern Time.
Oct 13, 2020 08:00 am ET
Neovasc to Sponsor Symposium on Treating Patients with Refractory Angina at TCT Connect 2020
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium entitled “Unmet Need in Treating Patients With Refractory Angina” at the 2020 TCT Connect Online Conference, taking...
Oct 13, 2020 08:00 am ET
Neovasc to Sponsor Symposium on Treating Patients with Refractory Angina at TCT Connect 2020
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 13, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that it will sponsor a symposium entitled "Unmet Need in Treating Patients With Refractory Angina" at the 2020 TCT Connect Online Conference, taking place October 14-18, 2020.
Sep 08, 2020 05:10 pm ET
Neovasc to Participate in H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2020) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that its management team will be participating in the 22nd Annual H.C. Wainwright Global Investment Conference on September 14-16, 2020. Fred Colen, Neovasc's President and CEO, will present on September 15 at 3:30 pm EDT.
Sep 08, 2020 05:00 pm ET
Neovasc to Participate in H.C. Wainwright & Co. 22nd Annual Global Investment Conference
via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of...
Sep 03, 2020 04:41 pm ET
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C. (the "Meeting").
Sep 03, 2020 04:34 pm ET
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C. (the...
Aug 17, 2020 09:00 am ET
Neovasc Announces Partial Prepayment of Convertible Debenture
via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”) exercised 501,000 of the remaining 1,149,910 common share purchase warrants (the “May Warrants”) issued pursuant...
Aug 17, 2020 09:00 am ET
Neovasc Announces Partial Prepayment of Convertible Debenture
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 17, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that Strul Medical Group LLC ("SMG") exercised 501,000 of the remaining 1,149,910 common share purchase warrants (the "May Warrants") issued pursuant to a Securities Purchase Agreement dated May 26, 2020 at an exercise price of US$2.634 per May Warrant for aggregate exercise proceeds to the Company of US$1,319,634.00 (the "Exercise Proceeds").
Aug 13, 2020 09:00 am ET
Neovasc Provides Corporate Update
via NEWMEDIAWIRE  -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today provided a corporate update on progress towards its value creation strategies.  Fred Colen, Chief Executive Officer of Neovasc, commented, “We are pleased...
Aug 13, 2020 09:00 am ET
Neovasc Provides Corporate Update
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 13, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today provided a corporate update on progress towards its value creation strategies.
Aug 12, 2020 02:41 pm ET
Neovasc Announces Closing of US$12.6 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2020) -  Neovasc Inc. (NASDAQ: NVCN)  (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a purchase price of US$2.77575 per common share for aggregate gross proceeds to the Company of approximately US$12.6 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company.
Aug 12, 2020 02:25 pm ET
Neovasc Announces Closing of US$12.6 Million Registered Direct Offering Priced At-The-Market
via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under the Nasdaq rules of an...
Aug 10, 2020 08:00 am ET
Neovasc Announces US$12.6 Million Registered Direct Offering Priced At-the-Market
via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 4,532,772...
Aug 10, 2020 08:00 am ET
Neovasc Announces US$12.6 Million Registered Direct Offering Priced At-the-Market
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2020) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 4,532,772 common shares at a purchase price of US$2.77575 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for aggregate gross proceeds to the Company of approximately US$12.6 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company. The Offering is expected to close on or about August 12, 2020, subject to customary closing conditions.
Aug 06, 2020 04:05 pm ET
Neovasc Announces Second Quarter Financial Results
via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of...
Aug 06, 2020 04:05 pm ET
Neovasc Announces Second Quarter Financial Results
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 6, 2020) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended June 30, 2020.
Jul 24, 2020 09:57 am ET
Neovasc Reducer(TM) Featured In Germany's Second Largest National Newspaper
Vancouver, British Columbia and Minneapolis, Minnesota and Frankfurt, Germany--(Newsfile Corp. - July 24, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company")  announced today that the Neovasc Reducer™ (the "Reducer") was featured in a supplement titled: "Volkskrankheiten" or "Common Diseases" in Frankfurter Allgemeine Zeitung (FAZ), the second largest national newspaper by circulation in Germany. The supplement will be mailed to subscribers, reaching an estimated audience of almost 500,000 and should be available in the waiting areas of physician offices across Germany over the coming months.
Jul 24, 2020 09:50 am ET
Neovasc Reducer™ Featured In Germany’s Second Largest National Newspaper
via NEWMEDIAWIRE --  Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a supplement titled: “Volkskrankheiten” or “Common Diseases” in Frankfurter Allgemeine...